Bahrain’s Supreme Council of Health (SCH) President and National Medical Task Force to Combat the Coronavirus (COVID-19) Chairman, Lieutenant-General Dr. Shaikh Mohammed bin Abdulla Al Khalifa, has revealed the kingdom has begun phase 3 clinical trials of Sinopharm’s COVID-19 vaccine.
Bahrain will be using the expertise of UAE-based artificial intelligence and cloud computing company, Group 42 and Chinese vaccine maker Sinopharm’s China National Biotec Group (CNBG) for conduct trials in the region.
A delegation of the officials of the potential vaccine, including those in charge of the experience in the UAE, Dr. Nawal Al-Kaabi and Dr. Waleed Abbas, in addition to representatives of Sinopharm and Group 42 visited Bahrain for initial discussions.
The kingdom will participate in the first global clinical trials for the third phase of WHO-listed potential coronavirus vaccine where the vaccine will be tested on 6,000 volunteer citizens and residents in Bahrain.
Efforts are being made by the kingdom and the National Medical Task Force to combat the coronavirus to fight the pandemic and ensure the health and safety of the citizens and residents.
The delegation lauded the kingdom’s efforts and measures to contain the pandemic through its precautionary and pre-emptive measures that are consistent with international standards and the recommendations of the World Health Organisation.
